This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Press Room

UK News

June 4, 2019   Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
March 25, 2019   Evidence from UK hospitals supports the value of the Oncotype DX test in avoiding unnecessary chemotherapy for patients with node-positive breast cancer
December 19, 2018   NICE expands recommendation for the Oncotype DX® test to more patients with early-stage breast cancer
December 11, 2018   New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score® test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions
October 22, 2018   New real-world evidence confirms value of the Oncotype DX® test in clinical practice for patients with early-stage breast cancer
June 3, 2018   Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
March 15, 2018   Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25
December 11, 2017   New results from large registry with 10-year follow up show excellent outcomes for patients with low Oncotype DX Breast Recurrence Score® results treated with hormonal therapy alone
September 11, 2017   Genomic test shows that half of under-40s with early breast cancer have excellent prognosis despite not having chemotherapy treatment
July 12, 2017   Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer
June 13, 2017   New data show important role of genomic testing in treatment of older breast cancer patients
March 20, 2017   Genomic Health’s Oncotype DX® breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal
February 6, 2017   NHS adoption of Oncotype DX® test leads to substantial reduction in unnecessary chemotherapy for UK breast cancer patients
December 12, 2016   New data demonstrate that Oncotype DX® can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy
October 10, 2016   Large study shows older breast cancer patients have worse outcomes
June 20, 2016   Updated NICE quality standard recommends Oncotype DX® in early-stage breast cancer
June 6, 2016   Oncotype DX presentations at 2016 ASCO® annual meeting reinforce Genomic Health’s leadership in optimising breast cancer treatment
May 31, 2016   Innovative Oncotype DX test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients
March 11, 2016   Five-year outcomes results from European ‘PlanB’ study show that breast cancer patients with low Oncotype DX Recurrence Score results can be spared chemotherapy despite having high-risk disease by traditional measures.
December 16, 2015   Major new study data demonstrates that the Oncotype DX test accurately predicts clinical breast cancer outcomes, bringing the total number of patients in prospective outcome studies to 50,000.
September 28, 2015   Large TAILORx outcomes study demonstrates 99% of patients with low Oncotype DX Recurrence Score results were breast cancer relapse-free following five years of hormone therapy alone.
February 5, 2015   As of April 1, 2015, the Oncotype DX test will be available, through an access scheme, as an option to help NHS clinicians in England decide whether to prescribe chemotherapy in people with early breast cancer.
September 25, 2013   NICE recommends Genomic Health’s Oncotype DX test to guide chemotherapy treatment decisions for qualified early-stage invasive breast cancer patients.


For global news please visit our U.S. website

Media Resources

For B-roll videos, images and infographics from Genomic Health, please visit our U.S.
Media Resources.


For high-resolution images, email your request to media@genomichealth.com.
Laboratory Vial
Genomic Health Lab
Laboratory Slide
Genomic Health Sample
Cancer Sample
Genomic Health Sample
Genomic Health Scientists
Genomic Health Scientists Working
Scientist in Lab
Genomic Health Cancer Samples Processed
Genomic Health Scientist in the Lab with Sample
Testing in the Lab
Processing Samples
Oncotype DX Samples
Genomic Health Oncotype DX
Oncotype DX in the Lab
Cancer Tissue
Samples Processed at Genomic Health
Tumor Tissue Processed